Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 12, 2000, Pages 2511-2518

  Bajzar, Laszlo ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b NONE   (Canada)

Author keywords

Coagulation; Fibrinolysis; Risk factors; Thrombolysis; Thrombosis

Indexed keywords

CARBOXYPEPTIDASE B; ENZYME PRECURSOR; METALLOPROTEINASE; PROTEIN C; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN;

BLOOD CLOT LYSIS; BLOOD CLOTTING; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME REGULATION; FEEDBACK SYSTEM; FIBRINOLYSIS; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; REVIEW; RISK FACTOR; THROMBOSIS;

EID: 0033675696     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.12.2511     Document Type: Review

References (76)

1. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface
2. Whole blood clot lysis: In vitro modulation by activated protein C
3. The cofactor role of protein S in the acceleration of whole blood clot lysis by activated protein C in vitro
4. The interaction of activated protein C and thrombin with the plasminogen activator inhibitor released from human endothelial cells
5. Mechanism of protein C-dependent clot lysis: Role of plasminogen activator inhibitor
6. Effect of activated protein C on the fibrinolytic components released by cultured bovine aortic endothelial cells
7. Platelet plasminogen activator inhibitor: Purification and characterization of interaction with plasminogen activators and activated protein C
8. The influence of thrombin and platelets on fibrin clot lysis rates in vitro: A study using a clot lysis system consisting of purified human proteins
9. Thrombin, a link between coagulation activation and fibrinolysis
10. The activated protein C-mediated enhancement of tissue-type plasminogen activator-induced fibrinolysis in a cell-free system
11. The effect of activated protein C on fibrinolysis in cell-free plasma can be attributed specifically to attenuation of prothrombin activation
12. Characterization of a stable form of human meizothrombin derived from recombinant prothrombin (R155A, R271A, and R284A)
13. Functional characterization of recombinant human meizothrombin and meizothrombin(desF1)
14. Purification and characterization of TAFI, a thrombin activatable fibrinolysis inhibitor
15. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent
16. Purification and characterization of a new arginine carboxypeptidase in human serum
17. Characterization of the gene encoding human TAFI (thrombin-activable fibrinolysis inhibitor; plasma procarboxypeptidase B)
18. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma
19. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties
20. Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms
21. Characterization of a carboxypeptidase in human serum distinct from carboxypeptidase N
22. An arginine specific carboxypeptidase generated in blood dining coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits
23. Isolation and characterization of the subunits of human plasma carboxypeptidase N (kininase I)
24. Plasma carboxypeptidases as regulators of the plasminogen system
25. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen
26. Coagulation-dependent inhibition of fibrinolysis: Role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma
27. Characterization of plasmin-mediated activation of plasma procarboxypeptidase B
28. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex
29. Activation and characterization of procarboxypeptidase B from human plasma
30. Thrombin interacts with thrombomodulin, protein C, and thrombin-activatable fibrinolysis inhibitor via specific and distinct domains
31. An integrated study of fibrinogen during blood coagulation
32. Thrombin Glu-39 restricts the P'3 specificity to nonacidic residues
33. Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C
34. Glu-192→Gln substitution in thrombin mimics the catalytic switch induced by thrombomodulin
35. Elements of the primary structure of thrombomodulin required for efficient TAFI activation
36. Molecular mechanisms of thrombin function
37. Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex
38. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor
39. Thrombomodulin in human plasma contributes to inhibit fibrinolysis through acceleration of thrombin-dependent activation of plasma procarboxypeptidase B
40. Thrombin generation in plasma: Its assessment via the endogenous thrombin potential
41. Thrombin mediated activation of factor XI in a TAFI (thrombin activatable fibrinolysis inhibitor) dependent inhibition of fibrinolysis
42. Factor XI dependent and independent activation of thrombin activatable fibrinolysis inhibitor (TAFI) in plasma associated with clot formation
43. The paradoxical role of thrombomodulin in the activation of thrombin activatable fibrinolysis inhibitor (TAFI) in plasma
44. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation
45. Human procarboxypeptidase U, or thrombin-activable fibrinolysis inhibitor, is a substrate for transglutaminases
46. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis
47. Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade, in human plasma
48. Role of cell-surface lysines in plasminogen binding to cells: Identification of alpha-enolase as a candidate plasminogen receptor
49. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA) II: Annexin II-mediated enhancement of t-PA-dependent plasminogen activation
50. Initial plasmin-degradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis
51. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained
52. Fibrinolysis mediated by tissue plasminogen activator disclosure of kinetic transition
53. Characterization of the binding of plasminogen to fibrin surfaces: The role of carboxy-terminal lysines
54. Superficial accumulation of plasminogen during plasma clot lysis
55. Interactions between staphylokinase, plasmin(ogen), and fibrin: Staphylokinase discriminates between free plasminogen and plasminogen bound to partially degraded fibrin
56. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor
57. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B
58. Purification and properties of a carboxypeptidase inhibitor from potatoes
59. Inducible carboxypeptidase activity: A role in clot lysis in vivo
60. A carboxypeptidase inhibitor from the medical leech Hirudo medicinalis
61. Activated human plasma carboxypeptidase B is retained in the blood by binding to alpha 2 macroglobulin and pregnancy zone protein
62. An arginine carboxypeptidase generated during coagulation is diminished or absent in patients with rheumatoid arthritis
63. Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin-activable fibrinolysis inhibitor
64. Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage
65. Activation of plasma procarboxypeptidase U in different mammalian species points to a conserved pathway of inhibition of fibrinolysis
66. Characterization of mouse thrombin-activatable fibrinolysis inhibitor
67. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI: In vivo evidence for a role of factor XI as an anti-fibrinolytic factor
68. A novel approach to arterial thrombolysis
69. A carboxypeptidase inhibitor markedly improves the potency of tPA in vivo
70. Inhibition of activated TAFI (thrombin-activatable fibrinolysis inhibitor) enhances tissue plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model
71. Activated human protein C prevents thrombin-induced thromboembolism in mice
72. Elevated bradykinin and decreased carboxypeptidase R as a cause of hypotension during tryptophan column immunoadsorption therapy
73. Anaphylatoxin inactivator of human plasma: Its isolation and characterization as a carboxypeptidase
74. C4a: The third anaphylatoxin of the human complement system
75. Isolation of three separate anaphylatoxins from complement-activated human serum
76. A steady-state template model that describes the kinetics of fibrin-stimulated Glu1- and Lys78-plasminogen activation by native tissue type plasminogen activator, and variants that lack either the finger or kringle 2 domain